Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of elexacaftor + tezacaftor + ivacaftor in cystic fibrosis with non-F508del ELX/TEZ/IVA-responsive CFTR mutations
2021-005320-38Phase 3Active
- Sponsor
- Vertex Pharmaceuticals
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cystic fibrosis (CF) comparing ELX/TEZ/IVA with Placebo (2 arms). Primary endpoint: Absolute change from baseline in percent predicted forced expiratory volume in 1 second. Started Dec 2021; status: active.
02
Drugs
elexacaftortezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2021-005320-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005320-38.